association

Full identifier: http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#association

Assigned to 1 class:

Minted in Nanopublication

 RAZ3PbvqVK comment approve/disapprove edit as derived nanopublication create new with same template

This is a local identifier minted within the nanopublication. http://purl.org/np/RAZ3PbvqVK...#association This association http://www.w3.org/2000/01/rdf-schema#label has label (this is a literal) "opdivo is a programmed death receptor 1 pd 1 blocking antibody indicated for the treatment of 1 1 1 2 1 3 a 1 4 1 5 1 5 a 1 6 1 7 a 1 8 a 1 9 a 1 1 a opdivo as a single agent or in combination with ipilimumab is indicated for the treatment of patients with unresectable or metastatic melanoma opdivo is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection opdivo is indicated for the treatment of patients with metastatic non small cell lung cancer nsclc with progression on or after platinum based chemotherapy patients with egfr or alk genomic tumor aberrations should have disease progression on fda approved therapy for these aberrations prior to receiving opdivo opdivo is indicated for the treatment of patients with metastatic small cell lung cancer sclc with progression after platinum based chemotherapy and at least one other line of therapy this indication is approved under accelerated approval based on overall response rate and duration of response see clinical studies 14 4 opdivo in combination with ipilimumab is indicated for the treatment of patients with intermediate or poor risk previously untreated advanced rcc opdivo is indicated for the treatment of adult patients with classical hodgkin lymphoma chl that has relapsed or progressed after autologous hematopoietic stem cell transplantation hsct and brentuximab vedotin or 3 or more lines of systemic therapy that includes autologous hsct this indication is approved under accelerated approval based on overall response rate see clinical studies 14 6 opdivo is indicated for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck scchn with disease progression on or after platinum based therapy opdivo is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who this indication is approved under accelerated approval based on tumor response rate and duration of response see clinical studies 14 8 opdivo as a single agent or in combination with ipilimumab is indicated for the treatment of adult and pediatric patients 12 years and older with microsatellite instability high msi h or mismatch repair deficient dmmr metastatic colorectal cancer crc that has progressed following treatment with a fluoropyrimidine oxaliplatin and irinotecan this indication is approved under accelerated approval based on overall response rate and duration of response see clinical studies 14 9 opdivo is indicated for the treatment of patients with hepatocellular carcinoma hcc who have been previously treated with sorafenib this indication is approved under accelerated approval based on tumor response rate and durability of response see clinical studies 14 1" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAZ3PbvqVK... This nanopublication date and time when the nanopublication was created http://purl.org/dc/terms/created was created on (this is a literal) "2021-07-03T15:33:18.413+02:00" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAZ3PbvqVK... This nanopublication links to the assertion template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate was created from the assertion template http://purl.org/np/RAManV5GZI... RAManV5GZI .
This is the identifier for this whole nanopublication. http://purl.org/np/RAZ3PbvqVK... This nanopublication links to the provenance template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate was created from the provenance template http://purl.org/np/RANwQa4ICW... RANwQa4ICW .
This is the identifier for this whole nanopublication. http://purl.org/np/RAZ3PbvqVK... This nanopublication links to the publication info template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate was created from the publication info template http://purl.org/np/RAA2MfqdBC... RAA2MfqdBC .
This is a local identifier minted within the nanopublication. http://purl.org/np/RAZ3PbvqVK...#sig sig http://purl.org/nanopub/x/hasSignatureTarget has as target This is the identifier for this whole nanopublication. http://purl.org/np/RAZ3PbvqVK... this nanopublication .
This is a local identifier minted within the nanopublication. http://purl.org/np/RAZ3PbvqVK...#sig sig http://purl.org/nanopub/x/hasAlgorithm has the algorithm (this is a literal) "RSA" .

Leoni Bücken, 3 Jul 2021, 13:33:18 UTC

References

Nanopublication Part Subject Predicate Object Published By Published On
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T13:33:18.413Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
opdivo is a programmed death receptor 1 pd 1 blocking antibody indicated for the treatment of 1 1 1 2 1 3 a 1 4 1 5 1 5 a 1 6 1 7 a 1 8 a 1 9 a 1 1 a opdivo as a single agent or in combination with ipilimumab is indicated for the treatment of patients with unresectable or metastatic melanoma opdivo is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection opdivo is indicated for the treatment of patients with metastatic non small cell lung cancer nsclc with progression on or after platinum based chemotherapy patients with egfr or alk genomic tumor aberrations should have disease progression on fda approved therapy for these aberrations prior to receiving opdivo opdivo is indicated for the treatment of patients with metastatic small cell lung cancer sclc with progression after platinum based chemotherapy and at least one other line of therapy this indication is approved under accelerated approval based on overall response rate and duration of response see clinical studies 14 4 opdivo in combination with ipilimumab is indicated for the treatment of patients with intermediate or poor risk previously untreated advanced rcc opdivo is indicated for the treatment of adult patients with classical hodgkin lymphoma chl that has relapsed or progressed after autologous hematopoietic stem cell transplantation hsct and brentuximab vedotin or 3 or more lines of systemic therapy that includes autologous hsct this indication is approved under accelerated approval based on overall response rate see clinical studies 14 6 opdivo is indicated for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck scchn with disease progression on or after platinum based therapy opdivo is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who this indication is approved under accelerated approval based on tumor response rate and duration of response see clinical studies 14 8 opdivo as a single agent or in combination with ipilimumab is indicated for the treatment of adult and pediatric patients 12 years and older with microsatellite instability high msi h or mismatch repair deficient dmmr metastatic colorectal cancer crc that has progressed following treatment with a fluoropyrimidine oxaliplatin and irinotecan this indication is approved under accelerated approval based on overall response rate and duration of response see clinical studies 14 9 opdivo is indicated for the treatment of patients with hepatocellular carcinoma hcc who have been previously treated with sorafenib this indication is approved under accelerated approval based on tumor response rate and durability of response see clinical studies 14 1
Leoni Bücken
2021-07-03T13:33:18.413Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T13:33:18.413Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T13:33:18.413Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T13:33:18.413Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T13:33:18.413Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T13:33:18.413Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T13:33:18.413Z

Raw

TriG(txt), JSON-LD(txt), N-Quads(txt), XML(txt)